Secondary Logo

Journal Logo

Bupropion Causes Misdiagnosis in Brain Dopamine Transporter Imaging for Parkinsonism

Honkanen, Emma A. MD*,†; Kemppainen, Nina MD, PhD*,†; Noponen, Tommi PhD; Seppänen, Marko MD, PhD; Joutsa, Juho MD, PhD*,†,§; Kaasinen, Valtteri MD, PhD*,†

doi: 10.1097/WNF.0000000000000359
Case Reports
Open

Objective The objective of this study was to report long-lasting effects of bupropion on brain dopamine transporter (DAT) in a patient with depression and parkinsonism.

Methods The patient was a 52-year old man who had been treated with 150 mg/d of bupropion for depression. The patient developed cognitive problems, bradykinesia, and reduced stride length for which he was scanned with [123I]FP-CIT single photon emission computed tomography after the recommended 1-week discontinuation of bupropion. Levodopa treatment trial was initiated without a response. Eleven months later, the patient was scanned for a second time after a 1-month stoppage of bupropion.

Results The first scan was abnormal with left putamen specific binding ratio of 1.99 (SDs from the reference value mean, −2.40), right putamen of 2.27 (SD, −1.84), left caudate of 2.33 (SD, −2.26), and right caudate of 2.29 (SD, −2.18). The second scan (after 1-month discontinuation) was normal, and specific binding ratios had increased from 5.2% to 31.7% in all striatal regions as compared with the first scan. Brain magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography imaging were normal, and there was no levodopa response or other features supporting neurodegenerative parkinsonism.

Conclusions Bupropion has previously generally been discontinued 1 week prior DAT imaging, which meets the recommended, albeit arbitrary, time interval of 5 plasma clearance half-lives before the scan. One-week discontinuation of bupropion before DAT imaging may be insufficiently short. Our case shows that longer medication washout and rescan may be needed when there is contradiction between the imaging result and clinical outcome in patients with medications affecting DAT binding.

*Department of Neurology, University of Turku

Division of Clinical Neurosciences, Turku University Hospital

Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, University of Turku

§Turku Brain and Mind Center, University of Turku, Turku, Finland.

Address correspondence and reprint requests to Emma A. Honkanen, MD, Division of Clinical Neurosciences, Turku University Hospital, POB 52, FIN-20521 Turku, Finland; E-mail: ealhonk@utu.fi

Conflicts of Interest and Source of Funding: The preparation of this article was financially supported by the Turku University Hospital and the Päivikki and Sakari Sohlberg Foundation. E.A.H. has received grants from the Department of Clinical Medicine of University of Turku and the Turku University Foundation and travel expenses from the Finnish Neurological Society and the Doctoral Programme in Clinical Research of the University of Turku and participated in a Finnish Neurological society meeting sponsored by several companies. J.J. received grants from the Academy of Finland (grant number 295580), the Finnish Medical Foundation, the Turku University Foundation, and Finnish governmental research funding (ERVA). He has received a grant from the Orion Research Foundation and participated in a Finnish Neurological society meeting sponsored by several companies. V.K. serves as an advisory board member of Abbvie and has received speaker's honoraria from Orion Pharma, Teva, GE Healthcare, Abbvie and NordicInfu Care AB;travel expenses from NordicInfu Care AB; and research funding from the Finnish Alcohol Research Foundation, the Päivikki and Sakari Sohlberg Foundation, the International Parkinson and Movement Disorder Society, and Finnish governmental research funding (ERVA). N.K., T.N., and M.S. report no disclosures. The authors declare that there are no conflicts of interest relevant to this work.

Data Availability Statement: Anonymized data will be shared by request from any qualified investigator.

Online date: July 30, 2019

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Striatal dopamine transporter (DAT) imaging can be used in the differentiation of degenerative parkinsonian disorders from conditions without such degeneration.1,2 Early to moderate Parkinson disease (PD) patients typically have a clear 50% to 60% loss in putaminal DAT binding compared with healthy individuals.3 However, several drugs that affect dopaminergic neurotransmission can influence the imaging outcome, thus biasing the interpretation. According to the prescription information for [123I]FP-CIT provided by the US Food and Drug Administration and the European Medicines Agency, amphetamine, benztropine, cocaine, methylphenidate, phentermine, sertraline, and several other drugs can induce changes in tracer binding.4,5 One of these drugs is bupropion, a norepinephrine-dopamine reuptake inhibitor, which is widely used as an antidepressant or as an aid to smoking cessation.6 Because of its dopaminergic mechanisms of action, bupropion has also shown some efficacy for dopamine agonist-mediated compulsive behaviors7 and apathy8 in PD.

Potentially interfering drugs should generally be stopped at least 5 plasma clearance half-lives before the scan to avoid effects on [123I]FP-CIT binding.9 Bupropion has an elimination half-life of approximately 20 hours,6 and according to the current recommendations, a 1-week washout should be sufficient for an accurate analysis of striatal DAT binding.

Here, we present a patient who had an abnormal result regarding [123I]FP-CIT single photon emission computed tomography (SPECT) after a 1-week discontinuation of bupropion, and the scan results later returned to normal after a considerably longer break in medication use.

Back to Top | Article Outline

CASE REPORT

A 52-year-old man with a medical history of atrial fibrillation had suffered from depression for several years. A psychiatrist referred the patient to a neurologist owing to problems in cognition, balance, and verbal communication. His antidepressant medications consisted of 225 mg/d of venlafaxine and 150 mg/d of bupropion. The patient was receiving no antiparkinsonian medication or other drugs known to have effects on the dopamine system. Family history was unremarkable.

A clinical examination showed mild bradykinesia in the left hand, mild slowness in his foot-tapping rate, and reduced stride length. Neuropsychological tests demonstrated some loss in memory functions and a lack of concentration. Blood and urine laboratory tests were unremarkable.

Brain magnetic resonance imaging showed no abnormalities, and the [18F]fluorodeoxyglucose positron emission tomography imaging was normal (Fig. 1). Because of partially asymmetric bradykinesia, [123I]FP-CIT SPECT was performed 7 days after discontinuation of bupropion use. Dopamine transporter imaging showed reduced binding bilaterally but particularly in the left putamen (left putamen specific binding ratio [SBR] of 1.99 [standard deviations from the reference value mean (SD), −2.40], right putamen SBR of 2.27 [SD, −1.84], left caudate SBR of 2.33 [SD, −2.26], and right caudate SBR of 2.29 [SD, −2.18]) (Fig. 2A, C).

FIGURE 1

FIGURE 1

FIGURE 2

FIGURE 2

After the first scan, a levodopa treatment trial with 450 mg/d was initiated without a clear response. Because of the lack of a levodopa response and the history of bupropion use, SPECT imaging was repeated 11 months after the first scan. The patient was now instructed to discontinue bupropion 4 weeks before the scanning. Bupropion (150 mg/d) was replaced by agomelatine (25 mg/d) owing to the long discontinuation. According to the Montgomery-Asberg Depression Rating Scale, the level of depression was similar between the 2 SPECT scans (37/60 and 39/60 at the time of the first and second scan, respectively), and the patient confirmed that the discontinuation of bupropion had been carried out as instructed before both scans.

The follow-up scan was analyzed using identical methods as those used for the first scan. The imaging results now showed quantitative overall improvement of the SBR values to a normal range (left putamen SBR of 2.62 [SD, −1.09], right putamen SBR of 2.50 [SD, −1.37], left caudate SBR of 2.45 [SD, −2.01], and right caudate SBR of 2.57 [SD, −1.62]) (Fig. 2B, D). The second scan was also evaluated visually as normal. There was a 31.7% increase in the [123I]FP-CIT SBRs in the left putamen and 5.2% to 12.2% increase in other regions (Fig. 2E). Importantly, nonspecific background binding stayed constant between studies (first study, 117.26 counts/voxel; second study, 117.48 counts/voxel). All brain images were coregistered together using a mutual information algorithm implemented in the Statistical Parametric Mapping software (SPM12, http://www.fil.ion.ucl.ac.uk/spm/software/spm12/).

Back to Top | Article Outline

DISCUSSION

Bupropion and its active metabolite, hydroxybupropion, cause a DAT occupancy of no more than 20% to 25% during treatment.10,11 This level of occupancy has been suspected to be too low to be the primary therapeutic mechanism of the drug.10,11 Nevertheless, our case demonstrated that the effect of a clinical dose of bupropion on DAT binding remains robust after a 1-week discontinuation, which may be owing to long-term adaptive mechanisms on dopamine transmission. This interferes with the [123I]FP-CIT SPECT results and can mislead the clinical interpretation. It has been previously reported that the use of bupropion could also interfere with the imaging results of [99mTc]TRODAT-1, another tropane-derivative DAT tracer; the binding values improved after 14 days of discontinuation of the medication but, importantly, still to lower levels than the reference values.12 In our patient, the binding returned to completely normal after a 1-month discontinuation of bupropion.

The case further suggested that the effect of bupropion may mimic neurodegeneration, as the loss of binding was not equal in the caudate and putamen, but it was predominantly seen in the left putamen 1 week after discontinuation. However, the DAT binding pattern was not typical for PD, because the reduced binding was seen mainly in the anterior part of the left putamen, not in the posterior putamen (Fig. 2C). It is also important to note that our patient had predominant motor symptoms in the left hand and the most severe bupropion-related DAT binding defect was observed in the ipsilateral side of the striatum, not in the contralateral hemisphere as is typically the case in PD. These differences in the regional distribution of DAT binding defects may be critical in the visual interpretation of scans that are taken from patients under dopaminergically active medications, such as bupropion. If a clear binding loss is detected, but the binding pattern does not appear typical for parkinsonism or clinically relevant, a potential effect of a drug is a possibility. However, it should be noted that, although our clinical findings were in agreement with a drug effect, and the scans were analyzed using semiquantitative and visual methods, we cannot exclude the possibility of minor inconsistencies in repeated DAT scans. In addition, the later scan can be characterized a scan without evidence of dopaminergic deficit, a common finding in clinical populations of patients with suspected PD.13 According to present knowledge, patients with scans without evidence of dopaminergic deficit who have true neurodegenerative parkinsonism are extremely rare,14 and a normal presynaptic dopamine function in functional imaging is currently considered an absolute exclusion criterion for PD.15

The prescription information for [123I]FP-CIT states that bupropion may interfere with imaging, but the impact of the drug on imaging has not been fully established.4,5 In many imaging centers, bupropion is discontinued for 7 to 10 days before [123I]FP-CIT scanning, which satisfies the suggested, albeit arbitrary, recommendation of 5 half-lives before the scan.9 Our case suggests that 5 half-lives may not be sufficient and that the interval should probably be increased to 1 month to avoid misdiagnoses of dopaminergic defects in neurological patients.

Back to Top | Article Outline

ACKNOWLEDGMENTS

The staff of the Department of Nuclear Medicine at Turku University Hospital is gratefully acknowledged.

Back to Top | Article Outline

REFERENCES

1. Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000;15(3):503–510.
2. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6(4):305–313.
3. Kaasinen V, Vahlberg T. Striatal dopamine in Parkinson disease: a meta-analysis of imaging studies. Ann Neurol 2017;82(6):873–882.
4. Food and Drug Administration (FDA), USA. Highlights of Prescribing Information for DatScan Ioflupane I 123 Injection. Published 2015. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022454Orig1s004lbl.pdf. Accessed July 13, 2019.
5. European Medicines Agency (EMA). Product Information for DatScan Ioflupane I 123 Injection. Published 2017. Available at: https://www.ema.europa.eu/en/documents/product-information/datscan-epar-product-information_en.pdf. Accessed July 13, 2019.
6. Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother 2006;6(9):1249–1265.
7. Benincasa D, Pellicano C, Fanciulli A, et al. Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinson's disease. Mov Disord 2011;26(2):355–357.
8. Krishnamoorthy A, Craufurd D. Treatment of apathy in Huntington's disease and other movement disorders. Curr Treat Options Neurol 2011;13(5):508–519.
9. Booij J, Kemp P. Dopamine transporter imaging with [123I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging 2008;35(2):424–438.
10. Árgyelán M, Szabó Z, Kanyó B, et al. Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. J Affect Disord 2005;89(1–3):115–123.
11. Volkow ND, Wang GJ, Fowler JS, et al. The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects. Biol Psychiatry 2005;57(6):640–646.
12. Lin C, Lane HY. Bupropion interferes with the image diagnosis of Parkinson's disease. Neuropsychiatr Dis Treat 2017;13:2637–2639.
13. Marek K, Chowdhury S, Siderowf A, et al. The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort. Ann Clin Transl Neurol 2018;5(12):1460–1477.
14. Nicastro N, Garibotto V, Badoud S, et al. Scan without evidence of dopaminergic deficit: A 10-year retrospective study. Park Relat Disord 2016;31:53–58.
15. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30(12):1591–1601.
Keywords:

bupropion; SPECT; parkinsonism; depression

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.